ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease

Area of Science:

• Biochemistry
• Immunology
• Cardiovascular Research

Background:

• Apolipoprotein A1 (ApoA1) is a key component of high-density lipoprotein (HDL), generally recognized for its atheroprotective properties.
• In the inflammatory environment near atherosclerotic lesions, ApoA1/HDL undergo modifications like oxidation and nitration, leading to altered structure and function.

Purpose of the Study:

• To investigate the formation and immunogenicity of modified ApoA1 neo-epitopes.
• To explore the role of ApoA1-specific IgG antibodies in pro-inflammatory responses and their association with cardiovascular diseases.

Main Methods:

• Analysis of ApoA1 modification in prooxidant and inflammatory conditions.
• Identification of neo-epitopes formed on modified ApoA1.
• Assessment of ApoA1-specific IgG antibody reactivity with Toll-like receptors (TLR)-2 and TLR4.
• Evaluation of epidemiological and functional data linking ApoA1 self-antibodies to cardiovascular events.

Main Results:

• Chemical modifications, particularly by neutrophil myeloperoxidase, generate immunogenic neo-epitopes on ApoA1.
• These neo-epitopes induce the production of proatherogenic ApoA1-specific IgG antibodies.
• These antibodies activate pro-inflammatory pathways via TLR-2 and TLR4 interaction.
• ApoA1 self-antibodies show prognostic value in cardiovascular diseases such as myocardial infarction and acute coronary syndrome.

Conclusions:

• Modification of ApoA1 in atherosclerotic environments leads to the formation of immunogenic epitopes.
• ApoA1 self-antibodies contribute to atherogenesis by initiating pro-inflammatory responses through TLRs.
• ApoA1 autoantibodies serve as important biomarkers for predicting cardiovascular disease risk.